Anas Younes, MD of Memorial Sloan Kettering Cancer Center, New York, NY discusses immune therapies for lymphoma with David Maloney, MD, PhD of Seattle Cancer Care Alliance, Seattle, WA, James Kochenderfer, MD of the National Cancer Institute, Bethesda, MD and Nathan Fowler, MD of the University of Texas MD Anderson Cancer Center, Houston, TX. Prof. Maloney talks about the role of CAR T-cells for B-cell and Hodgkin lymphoma. He explains that they are seeing encouraging response rates with anti-CD19 CAR T-cell therapy for lymphoma, with an approximately 50% complete remission rate in aggressive lymphomas, and overall response rates as high as 80%. Dr Kochenderfer talks about the data he presented; they treated patients with a low-dose chemotherapy conditioning regimen followed by anti-CD19 CAR T-cell therapy. The overall response rate in advanced lymphoma was 73%, with 55% complete remission (CR) and some responses have been durable. Dr Kochenderfer points out that these patients would not have alternative treatment options. They also discuss minimal residual disease (MRD) in this context. Dr Fowler talks about the developments in the field in terms of therapy. He points out that since the introduction of rituximab, they have been looking for new potential targets. He explains that we are seeing nice responses with therapies targeting CD19 with conjugated antibodies, monoclonal antibodies, BiTEs and DARTs. He also discusses other potential targets. Next, discuss lymphodepletion and Dr Kochenderfer talks about a trial with a fully human anti-CD19 CAR T-cell therapy. Further, the discuss targets for CAR T-cell therapy, such as ROR1, BCMA, and CD30. They then talk about PD-1/PD-L1 targeted agents for lymphoma and treatment duration. Finally, they talk about CR and whether some patients are cured with therapy.
Recorded at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.